Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial

By afschroeder • September 25, 2026

Shitara K, Wainberg Z, Tabernero J, Van Cutsem E, Coutzac C, De La Fouchardière C, Lee J, Rha SY, Kang YK, Fanning P, Forgie A, Mao C, Brickman D, Pons J, Tsiatis AC, Randolph S, Lee KW. Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial. Nat Med. 2026 Sep 24. doi: 10.1038/s41591-026-04700-3. Epub ahead of print. PMID: 42786305.

Tags: Hematology/Oncology, Publications

Suspected Pembrolizumab-Associated Perinuclear Antineutrophil Cytoplasmic Antibody (p-ANCA) Vasculitis With Progressive Kidney Injury in a Patient With Metastatic Renal Cell Carcinoma and Limited Renal Reserve: A Diagnostic Challenge

Goshtaseb R, Luu Y, Sarmosyan K, Lopez L, Drakaki A. Suspected Pembrolizumab-Associated Perinuclear Antineutrophil Cytoplasmic Antibody (p-ANCA) Vasculitis With Progressive Kidney Injury in a Patient[...]

Targeting lipidated amino acid deficiency mitigates fibrosis via a PPARα/CCL2 axis in metabolic dysfunction-associated steatohepatitis models

Anand SK, Das S, Arias F, Richard KS, Rohilla S, Ghrayeb A, McKinney MP, Wang L, Tan L, Ding J, Kumar D, Pandey N, Lee[...]

Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies

Yarchoan M, Llovet JM, Kelley RK, Finn R, Parikh ND, Tabrizian P, Burgoyne AM, Agopian VG, Sanford NN, Tran Cao HS, Padia SA, Vogel A,[...]